• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

In banner year, Lilly rewards CEO David Ricks with 24% boost in total pay to $26.6M

cafead

Administrator
Staff member
  • cafead   Mar 25, 2024 at 10:42: PM
via Eli Lilly’s revenue is tracking upward, its share price has climbed and its market cap has skyrocketed to the highest in the biopharma industry.

It's little wonder, then, that its executives, led by CEO David Ricks, are raking in the rewards. In 2023, Ricks received a 24% boost in pay from $21.4 million to $26.6 million, according to the company’s proxy filing.

article source